The aberrant overexpression and concomitant activation of members of the ErbB family of growth factor receptor tyrosine kinases plays key roles in promoting the growth and progression of a variety of solid tumor types. The long-term objective of the proposed studies is to understand the role of a novel protein degradation pathway in regulating ErbB-induced tumor progression. A central component of the pathway is a RING finger E3 ubiquitin ligase called Nrdpl that mediates the ubiquitination of ErbB receptors, thereby promoting their trafficking to degradative cellular compartments. The hypothesis guiding these studies is that the Nrdpl protein degradation pathway regulates ErbB-mediated cellular growth signaling by governing receptor levels through degradation. The two overarching goals for the current funding period are to understand the molecular mechanisms by which Nrdpl activity is regulated, and to understand the contribution of the Nrdpl pathway to ErbB receptor-induced mammary tumor growth and progression. These goals will be addressed with three specific aims. 1) The regulation of Nrdpl stability and activity by growth factors, signaling kinases and deubiquitinating enzymes will be examined using biochemical and molecular biological methods. The interactions among proteins involved in the pathway will also be examined. 2) The impact of the overexpression or loss of Nrdpl pathway components on the growth properties of cultured mouse and human mammary tumor cell lines will be examined using assays that measure proliferation, survival, motility and invasion. 3) The impact of Nrdpl on the growth of ErbB-induced mammary tumors in transgenic mouse models will be determined. These studies will assess whether overexpression of wild-type Nrdpl in the mouse mammary gland can suppress the latency, growth and metastasis of ErbB-induced mammary tumors, and whether overexpression of dominant-negative Nrdpl can induce mammary tumor formation or potentiate the latency or growth of ErbB-induced tumors. The results of these studies could implicate the Nrdpl pathway as a suppressor of tumor cell growth and progression, in turn suggesting that restoration or augmentation of pathway function in tumors could offer therapeutic benefit.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA123541-05
Application #
7778822
Study Section
Tumor Cell Biology Study Section (TCB)
Program Officer
Snyderwine, Elizabeth G
Project Start
2006-04-01
Project End
2012-02-28
Budget Start
2010-03-01
Budget End
2012-02-28
Support Year
5
Fiscal Year
2010
Total Cost
$235,778
Indirect Cost
Name
University of California Davis
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Wald, J H; Hatakeyama, J; Printsev, I et al. (2017) Suppression of planar cell polarity signaling and migration in glioblastoma by Nrdp1-mediated Dvl polyubiquitination. Oncogene 36:5158-5167
VanderVorst, Kacey; Hatakeyama, Jason; Berg, Anastasia et al. (2017) Cellular and molecular mechanisms underlying planar cell polarity pathway contributions to cancer malignancy. Semin Cell Dev Biol :
Printsev, Ignat; Curiel, Daniel; Carraway 3rd, Kermit L (2017) Membrane Protein Quantity Control at the Endoplasmic Reticulum. J Membr Biol 250:379-392
Hatakeyama, Jason; Wald, Jessica H; Rafidi, Hanine et al. (2016) The ER structural protein Rtn4A stabilizes and enhances signaling through the receptor tyrosine kinase ErbB3. Sci Signal 9:ra65
Savoy, Rosalinda M; Chen, Liqun; Siddiqui, Salma et al. (2015) Transcription of Nrdp1 by the androgen receptor is regulated by nuclear filamin A in prostate cancer. Endocr Relat Cancer 22:369-86
Printsev, Ignat; Yen, Lily; Sweeney, Colleen et al. (2014) Oligomerization of the Nrdp1 E3 ubiquitin ligase is necessary for efficient autoubiquitination but not ErbB3 ubiquitination. J Biol Chem 289:8570-8
Hatakeyama, Jason; Wald, Jessica H; Printsev, Ignat et al. (2014) Vangl1 and Vangl2: planar cell polarity components with a developing role in cancer. Endocr Relat Cancer 21:R345-56
Rafidi, Hanine; Mercado 3rd, Francisco; Astudillo, Michael et al. (2013) Leucine-rich repeat and immunoglobulin domain-containing protein-1 (Lrig1) negative regulatory action toward ErbB receptor tyrosine kinases is opposed by leucine-rich repeat and immunoglobulin domain-containing protein 3 (Lrig3). J Biol Chem 288:21593-605
Hong, Shiao-Ya; Shih, Yi-Ping; Li, Tianhong et al. (2013) CTEN prolongs signaling by EGFR through reducing its ligand-induced degradation. Cancer Res 73:5266-76
Liu, Wei; Hsu, Daniel K; Chen, Huan-Yuan et al. (2012) Galectin-3 regulates intracellular trafficking of EGFR through Alix and promotes keratinocyte migration. J Invest Dermatol 132:2828-37

Showing the most recent 10 out of 22 publications